References:
1. de Souza P, Friedlander M, Wilde C, Kirsten F, Ryan M.
Hypersensitivity reactions to etoposide. A report of three cases and
review of the literature. Am J Clin Oncol 1994;17:387-9.
2. Hoetelmans RM, Schornagel JH, ten Bokkel Huinink WW, Beijnen JH.
Hypersensitivity reactions to etoposide. Ann Pharmacother
1996;30:367-71.
3. Kasperek C, Black CD. Two cases of suspected immunologic-based
hypersensitivity reactions to etoposide therapy. Ann Pharmacother
1992;26:1227- 30.
4. Ogle KM, Kennedy BJ. Hypersensitivity reactions to etoposide. A case
report and review of the literature. Am J Clin Oncol 1988;11:663-5.
5. Etoposide. Package insert. Fresenius Kabi USA, LLC; 2019.
6. Turgay Yagmur I, Guzelkucuk Z, Yarali N, et al. Evaluation of
hypersensitivity reactions to cancer chemotherapeutic agents in
pediatric patients. Ann Allergy Asthma Immunol 2020;124:350-6.
7. Stockton WM, Nguyen T, Zhang L, Dowling TC. Etoposide and etoposide
phosphate hypersensitivity in children: Incidence, risk factors, and
prevention strategies. J Oncol Pharm Pract 2020;26:397-405.
8. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity
assessment in reporting adverse drug reactions. Am J Hosp Pharm
1992;49:2229-32.
9. Yu D, Sheets J, Suppes S, Goldman J. Characterization of Severe
Adverse Drug Reactions at a Free-Standing Children’s Hospital. J Clin
Pharmacol 2019;59:1569- 72.
10. Meyboom R. Intentional rechallenge and the clinical management of
drug-related problems. Drug Saf 2013;36:163-5.
11. Collier K, Schink C, Young AM, How K, Seckl M, Savage P. Successful
treatment with etoposide phosphate in patients with previous etoposide
hypersensitivity. J Oncol Pharm Pract 2008;14:51-5.